Woman practicing wellness in a sunlit natural setting, representing MyoBalan myo-inositol cycle support

MyoBalan: Věda o myo-inositolové cestě za folikulárním zdravím a podporou cyklu

TL;DR:

  • MyoBalan delivers the scientifically validated 40:1 myo-inositol to D-chiro-inositol ratio that mirrors the natural composition of ovarian follicular fluid, providing a precision foundation that generic inositol supplements miss.
  • Its four-pathway formula supports FSH receptor sensitivity, oocyte mitochondrial energy via Ubiquinol CoQ10 100mg, cycle-phase methylation with 5-MTHF 400mcg and hormonal cofactor activity with Zinc 150% NRV.
  • Unlike single-ingredient inositol products, MyoBalan combines the full pathway stack — Myo-Inositol, D-Chiro-Inositol, CoQ10, 5-MTHF, Zinc and Vitamin D3 — with full label transparency and zero proprietary blends.

The science behind myo-inositol has moved well beyond general cycle wellness. A growing body of peer-reviewed clinical research now distinguishes between inositol formulas that match ovarian physiology and those that merely add inositol as a commodity ingredient — and the difference is measurable at the cellular level.

Two women in their thirties walking through a sunlit botanical garden, representing natural hormonal wellness supported by MyoBalan myo-inositol formula

Table of Contents

Key Takeaways

Pathway Ingredient Mechanism
FSH receptor signalling Myo-Inositol 900mg Second messenger for FSH signal amplification
Ovarian insulin sensitivity D-Chiro-Inositol 22mg (40:1) Amplifies insulin signalling in ovarian cells
Oocyte mitochondrial energy Ubiquinol CoQ10 100mg Electron carrier in oocyte respiratory chain
DNA methylation Folate 5-MTHF 400mcg Active methylation cofactor — bypasses MTHFR
Hormonal synthesis Zinc Bisglycinate 15mg (150% NRV) Cofactor for sex hormone biosynthesis
Ovarian receptor modulation Vitamin D3 Supports vitamin D receptor activity in ovary

What Is Myo-Inositol?

Myo-inositol is a naturally occurring carbocyclic polyol that functions as a second messenger in multiple intracellular signalling cascades. Although it can be synthesised endogenously from glucose, supplemental concentrations are often necessary to achieve the tissue-level effects documented in clinical research — particularly within the ovarian microenvironment, where inositol demand is highest during follicular development.

Nine stereoisomers of inositol exist. The two with the most documented relevance to female reproductive physiology are myo-inositol (MI) and D-chiro-inositol (DCI). Critically, these forms are not interchangeable: MI mediates FSH signal transduction, while DCI amplifies insulin signalling within ovarian cells. In the landmark 1999 clinical trial published in the New England Journal of Medicine, Nestler et al. demonstrated that D-chiro-inositol supplementation improved ovulatory function and reduced androgen excess in women with polycystic ovary syndrome — establishing inositol signalling as a validated target for cycle support.

Understanding the distinction between MI and DCI is the starting point for evaluating any inositol supplement. A formula that provides only myo-inositol — or the wrong MI:DCI ratio — cannot replicate the physiological environment that research has studied.

The 40:1 Ratio: Why It Matters

The most significant advance in inositol formulation has been the identification and validation of the MI:DCI ratio naturally present in human follicular fluid. Analysis of the fluid surrounding maturing oocytes in the ovarian follicle consistently shows a ratio of approximately 40:1 MI to DCI — the biological environment in which the oocyte develops prior to ovulation.

Earlier supplementation trials used ratios of 5:1 or 20:1. While these produced some outcomes, they did not replicate follicular physiology. Research published by Papaleo et al. in Gynecological Endocrinology demonstrated that myo-inositol supplementation at physiologically relevant doses supported follicle development, improved hormonal parameters and facilitated ovulation induction in women with PCOS. The 40:1 formulation represents the current clinical gold standard, reflecting the composition of the follicular environment rather than an arbitrary mixture.

MyoBalan delivers Myo-Inositol 900mg and D-Chiro-Inositol 22mg — a 40.9:1 ratio. This precision distinguishes it from the majority of inositol products on the market, which use ratios optimised for metabolic insulin sensitisation (typically 3.6:1 or 5:1) rather than for ovarian follicular support.

FSH Receptor Sensitisation Pathway

Follicle-stimulating hormone (FSH) drives granulosa cell proliferation, aromatase expression and the selection of the dominant follicle for ovulation. But FSH binding to its receptor is only the first step — the intracellular signal must be transduced efficiently into a cellular response. Myo-inositol is the backbone of this second-messenger cascade.

When FSH binds its receptor on the granulosa cell membrane, it triggers phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2), releasing inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilises intracellular calcium, triggering the downstream signalling that ultimately drives follicular maturation. This entire cascade depends on the availability of free myo-inositol within the cell.

In conditions where inositol is depleted — a documented feature of the ovaries of women with PCOS and insulin resistance — FSH receptor signalling becomes attenuated. The result is reduced granulosa cell sensitivity to FSH even when circulating FSH concentrations are adequate. Supplementing myo-inositol at pharmacological doses replenishes the intracellular pool for IP3 synthesis, helping to restore signalling efficiency and supporting more consistent follicular development.

Woman seated calmly by a window in morning light, representing the focused hormonal wellness and oocyte quality supported by MyoBalan ubiquinol CoQ10 and 5-MTHF

Oocyte Quality and Ubiquinol CoQ10

Oocyte quality is widely accepted as the primary determinant of fertilisation success and early embryonic development. Unlike somatic cells, the oocyte must complete meiosis, sustain the energy demands of fertilisation and support early cell divisions entirely on its own mitochondrial reserves. This makes mitochondrial function in the oocyte a direct predictor of developmental competence.

Coenzyme Q10 (CoQ10) serves as the critical electron carrier between complexes I and II and complex III of the mitochondrial electron transport chain — the step that couples electron flow to proton pumping and ultimately ATP synthesis. Without adequate CoQ10, electron leak increases, generating reactive oxygen species that can damage spindle apparatus and oocyte mitochondrial DNA. In a study of particular significance, Ben-Meir et al. showed that CoQ10 supplementation restored mitochondrial function in aged oocytes and improved fertility outcomes, providing mechanistic validation for CoQ10 as an oocyte quality support nutrient.

MyoBalan provides CoQ10 as Ubiquinol — the pre-reduced, electron-rich form that mitochondria can utilise directly without requiring enzymatic conversion. Standard ubiquinone supplements must first be reduced to ubiquinol by NADH-cytochrome b5 reductase before entering the electron transport chain. This conversion step becomes progressively less efficient with age — making ubiquinol the biologically appropriate choice for women seeking meaningful mitochondrial support, particularly over 35.

5-MTHF: The Methylation Cofactor

Folate is essential for one-carbon metabolism — providing the methyl groups used in DNA synthesis, DNA repair and epigenetic regulation. During folliculogenesis, granulosa cells undergo rapid proliferation; during early embryonic development, cell division rates are extraordinary. Both phases create a high and sustained demand for folate-dependent methylation activity.

However, not all supplemental folate is biologically equivalent. Folic acid — the synthetic, oxidised form used in most supplements — must be enzymatically reduced to 5-methyltetrahydrofolate (5-MTHF) through a four-step pathway, with the rate-limiting step catalysed by methylenetetrahydrofolate reductase (MTHFR). Polymorphisms in the MTHFR gene — particularly C677T and A1298C — reduce enzymatic activity by 30–70%. These variants affect an estimated 40% of the adult population across most ethnic groups, and in women with the homozygous C677T variant, MTHFR activity may be reduced by up to 70%.

For these women, supplemental folic acid accumulates as unmetabolised folic acid (UMFA) rather than being converted, potentially competing with natural folate at the folate receptor. MyoBalan provides folate directly as 5-MTHF at 400mcg — the biologically active form, ready for immediate use in methylation reactions. This approach bypasses the MTHFR pathway entirely, ensuring that all women — regardless of genetic background — receive complete methylation support during the critical periconceptual window.

MyoBalan vs Generic Inositol Formulas

Feature MyoBalan Generic Inositol Supplement
MI:DCI ratio ✓ 40:1 — follicular fluid ratio ✗ Arbitrary (3.6:1, 5:1, 20:1 or unspecified)
Myo-Inositol dose ✓ 900mg — clinically studied range ✗ Often underdosed or ratio unspecified
CoQ10 form ✓ Ubiquinol 100mg (pre-reduced, active) ✗ Ubiquinone or absent entirely
Folate form ✓ 5-MTHF 400mcg — bypasses MTHFR ✗ Folic acid (requires MTHFR conversion)
Zinc inclusion ✓ Zinc Bisglycinate 15mg (150% NRV) ✗ Not typically included
Vitamin D3 ✓ Included for ovarian receptor modulation ✗ Not typically included
Label transparency ✓ All doses declared — no proprietary blends ✗ Proprietary blends hide individual doses

Discover MyoBalan with BioEssentials

MyoBalan is formulated for women who want a precision, multi-mechanism approach to cycle support — combining the clinically validated 40:1 inositol ratio with Ubiquinol CoQ10, 5-MTHF folate, Zinc Bisglycinate 150% NRV and Vitamin D3. Vegan, Non-GMO, Gluten-free and Eurofins tested. Made in France.

Explore MyoBalan — Precision Myo-Inositol Cycle Support Formula

Scientific pathway infographic showing MyoBalan's four mechanisms: FSH receptor signalling via myo-inositol, ovarian insulin sensitivity via D-chiro-inositol, oocyte mitochondrial energy via ubiquinol CoQ10, and DNA methylation via 5-MTHF

Frequently Asked Questions

What is the difference between myo-inositol and D-chiro-inositol?

Myo-inositol (MI) and D-chiro-inositol (DCI) are two stereoisomers of inositol that serve distinct cellular functions. MI acts as the second messenger for FSH receptor signalling in granulosa cells, while DCI amplifies insulin signalling specifically in ovarian tissue. They work synergistically at the correct ratio — MyoBalan provides both at the physiologically validated 40:1 ratio found in human follicular fluid, rather than in arbitrary proportions.

Why does the 40:1 MI:DCI ratio matter in practice?

The 40:1 ratio replicates the natural concentration of inositol forms found in the ovarian follicular fluid — the microenvironment where the oocyte matures prior to ovulation. Research on non-physiological ratios (such as 5:1 or 20:1) has shown inconsistent outcomes compared with the 40:1 formulation. By matching follicular physiology rather than simply adding inositol, MyoBalan supports the ovarian environment that clinical research has actually studied.

Why is 5-MTHF important for women with MTHFR variants?

Approximately 40% of women carry MTHFR gene variants that reduce their ability to convert synthetic folic acid into 5-MTHF — the active form used for DNA methylation and cell division. By providing folate directly in its 5-MTHF form, MyoBalan bypasses the MTHFR enzyme entirely. This ensures full methylation support during follicular development and the periconceptual period regardless of a woman's genetic background — a significant advantage for nearly half the female population.

What is ubiquinol and why is it better for oocyte support?

Ubiquinol is the pre-reduced, electron-rich form of CoQ10 that mitochondria use directly as an electron carrier in the respiratory chain. Standard supplements provide ubiquinone, which must be enzymatically converted to ubiquinol before it can function — a conversion step that declines with age. For oocyte mitochondrial support, particularly in women over 35, providing CoQ10 already in its active ubiquinol form avoids this age-dependent bottleneck and supports more direct mitochondrial energy availability.

Can MyoBalan be combined with other BioEssentials formulas?

MyoBalan's ingredient profile does not overlap with formulas such as FEMBALANCE, SLEEPWELL or MAGNESIUM 5. Its declared doses make it straightforward to evaluate total daily intake when combining formulas. For women in a preconception phase or managing a health condition, we always recommend discussing supplementation with a qualified healthcare professional before starting or combining any regimen.

Scientific References

These statements have not been evaluated by the Food and Drug Administration. BioEssentials products are food supplements intended to support general wellness and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any supplement programme.

Zpět na Zprávy

Featured collection

Zobrazit vše